News

As per the agreement terms, Lundbeck will pay an upfront amount of around DKK750m (€100m). The company is further required to pay up to DKK6bn (€805m) to Prexton in development,

The study showed that ALXN1210 achieved non-inferiority to Soliris (eculizumab) in complement inhibitor treatment-naïve patients with PNH based on the co-primary endpoints of transfusion avoidance and normalization of

ZW49 was developed by leveraging ZymeLink in combination with Zymeworks’ flagship Azymetric bispecific platform. The Company expects to file an Investigational New Drug (IND) application this year in order

This follows the FDA’s acceptance in February 2018 of an Investigational New Drug (IND) Application by the Company for the potentially ground-breaking drug. Fast Track Designation is one

Akcea, which is an affiliate of Ionis, is a biopharmaceutical company engaged in the development and commercialization of drugs to treat patients with serious rare diseases. Inotersen is

Foghorn initially commenced operations in 2016, and developed a Gene Traffic Control product platform to discover and develop drugs based on insights into the chromatin regulatory system that

CrownBio provides the world’s largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes

Proteostasis Therapeutics president and CEO Meenu Chhabra said: "This is the second important regulatory designation PTI-428 has been granted from the FDA this week, highlighting our amplifier’s potential to

The trial was evaluating the safety and efficacy of the investigational therapy in ambulatory and non-ambulatory children and adolescents with the genetic disorder. According to Solid Biosciences, the